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MICRORNA EXPRESSION AND DISEASE CORRELATION IN A HISPANIC LUPUS
COHORT
Thandiwe W. Jere, MBBS, M.S.
University of Nebraska Medical Center, 2018
Advisor: Kaihong Su, PhD.
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with varying clinical
presentation and severity in different ethnicities/races. Micro-RNAs (miRNAs) modulate the
immune system, and there is a growing interest in their role in SLE pathogenesis and disease
presentation. Studies on miRNAs expression in SLE have been done in Caucasians and Asians but
no comprehensive profiling has been done in Hispanics. This cross-sectional study of a Hispanic
cohort of SLE patients (n =185) and healthy controls (HC) (n =185) from the Dominican Republic
determined the expression of 10 selected miRNAs and their correlation to inflammatory markers
and auto-antibody production in SLE. The expression levels of miR-451a miR-16-5p, miR-126-5p,
miR-146a-5p were significantly higher in SLE patients than in HC. miR-125a-3p and miR-155-5p
were lower in SLE while miR-21-5p, miR-142-3p, miR-148a-3p, and miR-223-5p showed no
difference between SLE and HC. MiR-16-5p correlated with anti-Sm and IFN-γ; miR-155-5p
correlated with anti-SSA/Ro, IL-1β, and IL-12p70; and miR125a correlated with C4 and IL-1β. We
also show that miR451a and miR125a affect activation of neutrophil-like NB4 cells, pointing to
their potential role in neutrophil mediated inflammation in SLE. This novel study in a Hispanic
cohort shows differential expression of miRNAs in SLE and significant correlation with markers
of inflammation, setting an important premise for further study on their mechanism of action.
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INTRODUCTION
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease hallmarked by the
production of autoantibodies against nuclear antigens, and excessive inflammatory responses that
affect multiple organs (1). The disease is characterized by hyperactive T and B cells, leading to
autoantibody production and formation of Immune complexes that deposit in end organs (1).
The prevalence of SLE is higher in females with a nine to one ratio compared to males. SLE
is heterogeneous in nature and differences in disease development, clinical manifestation and
disease activity have been seen in different individuals and ethnicities (2). Hispanics and Black/
African Americans have higher prevalence, earlier onset of disease, and more frequent clinical
complications than Caucasians and Asians (3, 4). It has also been seen that Hispanics have a higher
prevalence and incidence of Lupus Nephritis than Caucasians. Multiple genetic and environmental
factors are known to influence the development and nature of the disease and contribute to this
variation and complexity (2).
Central to the organ damage that occurs in SLE is the tissue deposition of antibody-antigen
immune complexes (ICs) that trigger plasmacytoid dendritic cell (pDCs), T cells, and macrophages
to produce pro-inflammatory cytokines (5). ICs also activate the complement system and immune
effector cells such as neutrophils, which are the key mediators of tissue damage in SLE, owing to
their release of reactive oxygen species, tissue damage proteases and enhanced neutrophil
extracellular traps (NETs) formation (6).
Although efforts have been made to understand the pathogenesis of SLE, there is still a lack of
sufficient knowledge about the exact mechanisms underpinning the disease to develop effective
therapies for SLE patients. Recent studies indicate that micro-RNAs (miRNAs) are involved in the
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development of SLE, which gives new insight into the pathogenesis of SLE and might lead to the
finding of new therapeutic targets (1, 7).
Micro-RNAs are small non-coding RNAs that regulate gene expression. They are known to
play a critical role in the development of the immune system, as well as regulation of the innate
and adaptive immune systems (8). Altered expressions of miRNAs are seen in autoimmune diseases
such as SLE and rheumatoid arthritis, as well as in cancer (8). Considering this, miRNAs have
become an area of interest owing to their contributory role to disease pathogenesis. In SLE, there
is activation of both the innate and adaptive immune systems, and specific miRNAs are linked to
some key processes involving both. Some of these processes include: interference in the Type 1
Interferon (IFN)-signaling pathway (miR-146a, miR-155) (9, 10 ); DNA hypo-methylation in T
cells (miR-21, miR-126, miR-148a) (11, 12 ); aberration in inflammatory chemokine pathways
(miR-125a) (13 ); neutrophil development and function (miR125a, miR223, miR451a) (14, 15 );
B-cell hyperstimulation and T-cell over-activation (miR-142-3p/5p) (16 ); induction of regulatory
T cells (miR-16) (17 ); and regulation of myeloid cell development ( miR-223) (18, 19 ).
With the arising knowledge about miRNAs involvement in SLE, studies have determined the
differential expression in SLE. Most of the profiling studies have been done in Caucasian and Asian
populations. However, there are no studies that have profiled miRNA expression patterns in
Hispanic SLE patients. In addition, variations in these patterns have been seen in different races
and this lack of consistency raises the question of whether there is race- and ethnic-specific miRNA
expression signatures in SLE (7).
Therefore, we hypothesize that miRNAs are dysregulated in Hispanic SLE patients compared
to healthy controls(HC) and the dysregulated miRNAs may contribute to the pathogenesis of SLE.
The purpose of the study was to determine the expression of cell -free circulating miRNAs in serum
in a cohort from the Dominic Republic. Although several miRNAs have been linked to SLE
pathogenesis, we selected 10 miRNAs that have been dominantly implicated in inflammation and
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autoimmunity and shown to be deregulated from comprehensive review articles and studies done
in other populations. We further tested the correlation of miRNA profiles with serum markers of
inflammation (complement C3 and C4), inflammatory cytokines, and SLE autoantibodies (antidouble stranded DNA (dsDNA), anti-Smith (Sm), anti-Ribonucleic Protein (RNP), antiRo/Sjogren’s syndrome antigen A (SSA) and anti-La/Sjogren’s syndrome antigen B (SSB).
Further, we tested the functional effects of up or down-regulation of miR125a and miR451a in
neutrophil-like NB4 cells.
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MATERIALS AND METHODS
Study Participants
The study participants were recruited from the Hospital Jose Maria Cabral y Baez in the
Dominican Republic. We selected patients diagnosed with SLE (n = 185) according to the 1997
Revised American College of Rheumatology (ACR) criteria. Age- and sex-matched HC (n = 185)
were also recruited from the same community. The study was approved by the Institutional Review
Board (IRB) affiliated with the hospital and the University of Nebraska Medical Center (UNMC).
All participating subjects provided written informed consent according to the Declaration of
Helsinki. Data on medical history, clinical manifestations, SLE Disease Activity Index (SLEDAI)
score, and Systemic Lupus International Collaborating Clinics (SLICC) scores were collected from
review notes. Blood was collected from SLE patients and HC. The samples were processed, and
serum extracted before shipment (with dry ice at -78.5 °C) to the Su lab at UNMC where they were
stored at -80 °C until analysis.

Measure of autoantibody titers and levels of complement C3 and C4
Auto-antibody (anti-dsDNA, anti-Smith, anti-U1RNP, anti-Ro/SSA and anti-La/SSB) titers in
patients’ serum samples were obtained using the respective FDA-cleared ELISA-based clinical
tests from Euroimmun US (Mountain Lakes, NJ). The serum levels of complements (C3 and C4)
were determined by ELISA kits obtained from Cell Sciences (Newburyport, MA).

Total RNA extraction
Total RNA was extracted from serum using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden,
Germany). A starting volume of 200 µl was maintained for all samples. Serum was lysed with
QIAzol Lysis Reagent (Qiagen) at room temperature for 5 min. To control for miRNA individual
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variation across samples, an exogenous spike-in control was used, namely C. elegans miRNA
mimic. Chloroform was added to the mix, shaken vigorously, and incubated for 3 min at room
temperature, followed by centrifuging for 15 min at 12,000 x g at 4 °C for phase separation. The
upper aqueous phase was mixed with 80% ethanol and centrifuged at 8000 x g for 30 s at room
temperature in a RNeasy MinElute spin column. This step was repeated using buffers supplied with
the kit to wash the column. The final wash was performed with 80% ethanol, and centrifuged for 2
min at 8000 x g. The RNA was then eluted in RNase-free water provided with the kit. To test for
RNA extraction efficiency, the eluted RNA sample was analyzed using the Agilent 2100
Bioanalyzer (Agilent Technologies, Waldbronn, Germany) in the DNA Microarray Core Facility
(UNMC, NE, USA).

Quantification of miRNA by qPCR
Generation of cDNA was done using the Mir-X miRNA First-Strand Synthesis kit (Clontech,
CA, USA) as per the manufacturer’s instructions and reverse transcription done using an Applied
Biosystems 2720 Thermal Cycler. The miRNA-specific 5’ primers for qPCR were obtained from
Invitrogen, CA, USA after sequence validation from the miRbase database.
The reaction mix for qPCR was made using the Mir-X miRNA q-RT PCR SYBR kit (Clontech,
CA, USA) as per the manufacturer’s instructions with the following volume adjustments: 5.1 µl
ddH2O, 7 µl SYBR Advantage Premix (2X), 0.3 µl ROX dye (50X), 0.3 µl miRNA-specific 5’
primer, 0.3 µl MRQ 3’ primer, and 2 µl sample cDNA. The qPCR was performed with a 7900HT
Fast Real-Time PCR system (Applied Biosystems, CA, USA) in a

384-well clear plate with

cycling conditions as per the manufacturer’s protocols. All reactions were done in duplicate.
To effectively determine the expression levels of target miRNAs by qPCR, it is important to
standardize to internal controls that account for differential miRNA expression that occurs due to
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individual sample variation. There is no known universal reference control; therefore, we analyzed
the expression of 2 miRNAs, namely miR-24-2-5p, and miR-484. U6snRNA has been widely used
as a reference control in miRNA profiling; therefore, we also included it in our study to select the
best stably expressed that would serve as internal control. Data were processed using the RQ
Manager 1.2 software (Applied Biosystems, CA, USA).

Inflammatory Cytokine/Chemokine assay
To determine and quantify the presence of inflammation, a 13-panel bead based immuno-assay
was carried out using the LegendPlex Multi-analyte flow assay kit (BioLegend Inc., CA, USA) as
per the manufacturer’s instructions. The assay measured Interleukins 1β, 6, 8,10,12p70, 17A, 18,
23, and 33; Interferons α and γ; Tumor Necrosis Factor-α, and MCP-1. Briefly, SLE

(n =100)

and HC (n = 100) serum samples were diluted 2-fold with the provided assay buffer and incubated
with fluorescence-encoded beads and biotinylated detection antibodies on a plate shaker for 2 hours
at room temperature. Streptavidin-phycoerythrin (SA-PE) was then added followed by further
shaking for 30 minutes. After centrifuging for 5 minutes, the supernatant was removed, and the
beads washed two times with the provided wash buffer. Samples were read on a flow cytometer in
FACS tubes and the concentrations determined from standard curves generated for each
cytokine/chemokine.

Cell culture
NB4 cell line was cultured and maintained in DMEM High Glucose medium (GE Lifesciences,
Utah) supplemented with 10% Fetal bovine serum (FBS), 1% HEPES, free acid (GE Lifesciences,
USA), 1% Sodium Pyruvate (100mM) (Mediatech Inc. USA), 1% GlutaMax(100X)
(ThermoFischer, USA) and 1% Penicillin-Streptomycin (ThermoFischer, USA).
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Plasmid preparation
Vectors containing precursor miR451a mimic, miR451a scrambled control, miR125a inhibitor
and miR125a inhibitor scrambled control (GeneCopoeia, MD, USA) were grown overnight on
Agar plates at 37 °C. Colonies were picked, followed by incubation in Luria broth (LB) at 37 °C in
a shaker overnight. Following this, plasmid extraction was done using the EndoFree plasmid maxi
kit (Qiagen, Germany) as per the manufacturer’s instructions.

Transfection of NB4 cells
Cells were plated overnight in 2.5 ml growth medium in a 6 well plate at a density of
5 x 105 cells/ml, followed by transfection using the TransIT-X2 Dynamic Delivery System (Mirus
Bio LLC, USA) as per the manufacturer’s instructions. The transfected cells were incubated for 48
hours at 37 °C and 5% CO2. This was followed by selection using Puromycin 0.1ug/ml, and further
incubation for 48 hours. Transfection efficiency was determined by flow cytometry. Differentiation
to terminal neutrophil-like cells was induced by administration of All-Trans retinoic acid (ATRA)
1ug/ml.

Oxidative burst assay using Dihydrorhodamine (DHR)
The differentiated cells were harvested and resuspended in FACS buffer (FBS/PBS), followed
by incubation with DHR dye (Sigma-Aldrich, USA) at room temperature for 10 mins. Stimulation
was done by adding 5ug/ml ovalbumin: anti-ovalbumin immune complex and incubating in a water
bath at 37°C for 30 mins. The tubes were placed on ice for 10 mins to stop all reactions, followed
by centrifuging and washing using PBS. Cell pellets were resuspended in 200ul FACS buffer and
measurement done on a Novocyte flow cytometer (Acea biosciences, Inc, CA, USA).
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Statistical Analysis
All the analyses were done using either SPSS 24.0 (IBM Corp, NY, USA) or GraphPad Prism
7.03 (GraphPad Software, Inc. CA, USA). Values were normalized to the selected internal controls
and miRNA relative levels were calculated using the delta-delta Ct method. Student’s t-test was
used to compare the results obtained for SLE and HC. Correlation analysis was done using
Spearman’s non-parametric correlation to compare miRNA relative levels with levels of serum
autoantibodies

(anti-dsDNA,

anti-Smith,

anti-U1RNP,

anti-Ro/SSA

and

anti-La/SSB),

complement C3, C4, and inflammatory cytokines. P values <0.05 were considered statistically
significant.
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RESULTS
The characteristics of the SLE study subjects and the age- and sex-matched HC are shown in
Table 1. Clinical characteristics obtained from the SLE patients revealed a higher prevalence of
arthritis, renal disease, and muco-cutaneous disease.

Differential miRNA expression in SLE
We tested the expression of 2 miRNAs and 1 snRNA to select the best internal reference
control. These included mir-24-2-5p, miR-484, and U6 (Figure 1). There was a difference in the
mean Ct values for U6 snRNA (P = 0.001) between SLE and HC. Meanwhile, there was no
difference in the mean Ct values for miR-24-2-5p (P = 0.09) and miR-484 (P = 0.51) between SLE
and HC samples. Accordingly, miR-24-2-5p and miR-484 were selected as the internal controls.
Relative expression levels of the 10 miRNAs of interest in patients with SLE and HC,
normalized to miR-24-2-5p and miR-484 and expressed as delta CT are shown in Figure 2. The
expression levels of miR-451a (P < 0.0001), miR-16-5p (P <0.0001), miR-146a-5p (P =0.008),
and miR126-3p (P = 0.004) were higher in SLE patients than in HC. The expression levels of miR125a-3p (P < 0.0001) and miR- 155-5p (P = 0.004) were lower in SLE than in HC. However, the
serum levels of miR-21-5p, miR-142-3p, miR-148a-3p, and miR-223-5p were not different
between SLE patients and HC. The corresponding relative fold changes are shown in Figure 3.

Dysregulated miRNAs correlate with autoantibodies, complement and cytokines
Spearman’s correlation analyses were done between autoantibodies and serum markers of
inflammation and miR16-5p, miR-125a-3p, miR126-3p, miR-146a-5p, miR-155-5p and miR-451a
(Table 2). There was observed correlation between miR-16-5p and C4 (r =0.242, P =0.003). In
addition, miR16-5p inversely correlated with anti-Sm antibody (r = -0.12, P = 0.023). miR125a
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inversely correlated with C4 (r = -0.207, P = 0.005). There was observed correlation between
miR155-5p and anti-SSA (r = 0.226, P = 0.003), and inversely with anti-Sm (r = -0.163, P =0.04).
There was no correlation observed between C3, anti-dsDNA, anti-SSB, anti-RNP and all the
miRNAs.
As a measure of inflammation, a panel of 13 cytokines was tested in the SLE serum samples
and spearman’s correlation analysis done with the differentially expressed miRNAs (Table 4).
There was observed correlation between miR16-5p and IFN- γ, miR125a-5p and Il-1β. miR155-5p
correlated with IL-12p70 and inversely with IFN-γ.

Transfection with miR125a and miR451a affects oxidative response in NB4 cells
Neutrophils have been shown to play an important role in end organ damage in SLE (5,6) To
determine if miRNAs dysregulated in SLE patients have functional effects in neutrophils, we used
neutrophil-like NB4 cell line as a model system because of the short half-life of primary
neutrophils. NB4 cells were stably transfected with miR125a inhibitor and miR451a mimic to
imitate the expression pattern seen in SLE. Non-targeting scrambled sponge control vectors were
used as negative controls.
Upon stimulation with ovalbumin: anti ovalbumin immune complexes, NB4 cells stably
transfected with miR125a inhibitor showed increased oxidative burst, compared to the negative
control, and untransfected cells (Fig 4). We also observed increased oxidative burst in cells stably
transfected with miR45a mimic, compared to the unstransfected and negative scrambled controls
(Fig 5). Collectively, these results show that inhibition of miR125a and over-expression of
miR451a enhanced the oxidative response in neutrophil-like NB4 cells stimulated with immune
complexes.
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Figure 1: Selection and validation of miR-24-2-5p and miR-484 as internal controls for
normalization.
Comparison of mean Ct values derived from qPCR of the 3 miRNA internal controls (U6
SnRNA, miR-24-2-5p, and miR-484) between SLE (n = 44) and HC (n = 48). The error bars
represent the standard deviation from the mean. Student t-tests were used to determine mean
differences between groups with level of significance P < 0.05. Reactions were run in duplicate.
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Figure 2: Relative expression levels of miR-16-5p, miR125a-3p miR126-3p, miR146a-3p,
miR155-5p and miR451a. The CT values from qPCR were normalized to miR24-2-5p and miR484 to obtain the delta CT. The SLE group was compared to HC by Mann Whitney’s two tailed
test. The error bars represent the standard deviation of the mean. P <0.05 was statistically
significant.
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Figure 3: Relative miRNAs fold change in SLE patients compared to HC
Values for healthy control samples (n = 185) were normalized to 1(shown by the dotted line).
Fold changes of the 10 miRNAs in SLE (n = 185) were determined using the 2^−ΔΔCt method and
normalized to the endogenous controls miR-24-2-5p and miR-484. The error bars represent the
standard deviation of the mean (SD). The numbers represent the relative fold changes. All qPCR
assays were run in duplicate for each miRNA. Student t-tests were used to compare means with
level of significance P < 0.05*.
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Figure 4: Oxidative burst measurement of NB4 cells transfected with miR125a by flow
cytometry using DHR.
(a) Fluorescence histogram of the metabolic response in NB4 cells stably transfected with
miR125a inhibitor, miR-125a inhibitor scrambled control and untransfected cells stimulated with
5ug/ml ovalbumin: anti-ovalbumin immune complex.
(b) Quantitative representation of the mean fluorescence in the three groups. Three independent
transfection and activation assays were done, and the error bars represent the standard deviation of
the mean. CmiR125a miR125a scrambled control, HmiR125a miR125a inhibitor.
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Figure 5: Oxidative burst measurement of NB4 cells transfected with miR451a by flow
cytometry using DHR.
(a) Fluorescence histogram of the metabolic response in NB4 cells stably transfected with
miR451a mimic, miR451a scrambled control and untransfected cells stimulated with 5ug/ml
ovalbumin: anti-ovalbumin immune complex.
(b) Quantitative representation of the mean fluorescence in the three groups. Three independent
transfection and activation assays were done, and the error bars represent the standard deviation of
the mean. CmiR451a mi451a scrambled control HmiR451a miR451a mimic.
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Table 1: Clinical characteristics of SLE patients and healthy controls
Characteristics

SLE

HC

Age mean ± SD years

33 ± 12.3

32 ± 8.73

SLEDAI score, mean ± SD

5 ± 4.17

N/A

Sex, % (n)

Female 94 (174)

96 (144) ;

Male 6 (11)

Male 4 (6)

Disease Manifestation % (n)*

N/A

Hematological

36.4 (56)

Muco-cutaneous

41.6 (65)

Renal disease

55.2 (86)

Neuro-psychiatric

16.2 (25)

Cardiopulmonary

24 (37)

Arthritis

66.9 (104)

Autoantibodies, %

N/A

Anti-dsDNA

57

Anti-Sm

34

Anti-RNP

44.2

Anti-SSA/Ro

48

Anti-SSB/La

6.4

dsDNA, double stranded DNA; Sm, Smith; RNP, ribonucleic protein; SSA, Sjogren’s Syndromerelated antigen A; SSB, Sjogren’s Syndrome Antigen B; SLEDAI, Systemic Lupus Erythematosus
Disease Activity Index.
*Disease manifestation is shown as a percentage of those that had the clinical features against the
total N.
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Table 2: Correlation between Complement C3, C4, autoantibodies, and the dysregulated miRNAs.

Anti-

Anti-

Anti-

Anti-

Anti-

C4

dsDNA

SSA

Sm

RNP

SSB

(mg/dl)

(IU/ml)

(RU/ml)

(RU/ml)

(RU/ml)

(RU/ml)

r -0.03

0.242

0.059

-0.012

-0.12

-0.120

-0.034

P 0.60

0.003*

0.483

0.134

0.023*

0.143

0.675

r 0.014

-0.207

0.006

0.143

0.03

0.021

-0.048

P 0.861

0.005*

0.942

0.079

0.717

0.799

0.557

r 0.090

0.023

0.091

-0.063

-0.064

0.067

-0.125

P 0.268

0.780

0.26

0.442

0.435

0.412

0.123

r 0.002

0.15

-0.10

0.226

-0.163

P 0.977

0.855

0.903

0.003*

0.044*

0.613

0.536

r 0.065

0.042

-0.09

-0.013

-0.09

-0.055

0.008

P 0.426

0.608

0.269

0.873

0.271

0.500

0.923

C3
(mg/dl)
miR-16-5p

miR-125a-3p

miR-146a-5p

miR-155-5p

miR451a

r Spearman’s non- parametric correlation; P < 0.05 *

-0.042

-0.05
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Table 3: Correlation between dysregulated miRNAs and inflammatory cytokines in SLE patients

IFN-gamma
miR-16-5p

miR-125a-3p

miR-155-5p

IL-1β

IL-12p70

r = 0.311

r = - 0.23

r = 0.07

P = 0.03*

P = 0.10

P = 0.34

r = - 0.072

r = -0.285

r = -0.54

P = 0.497

P = 0.006*

P = 0.01

r = -0.255

r = -0.01

r = 0.248

P = 0.014*

P = 0.47

P = 0.017*

IL-1β Interleukin-1Beta, IFN-γ Interferon Gamma, IL-12p70 Interleukin 12-p70. P < 0.05*
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DISCUSSION
Quantitative PCR analysis of 10 selected serum miRNAs in this study cohort showed a
difference in the expression of miR-16-5p, miR-125a-3p, miR126-3p, miR-146a-5p, miR-155-5p,
and miR-451a in SLE patients compared to the age- and sex-matched healthy controls. Whilst miR16-5p, miR-125a-3p, miR126-3p and miR-451a were overexpressed in the SLE group; there was
reduced expression of miR-155-5p and miR-146a-5p. Further correlation analyses of these 6
miRNAs with autoantibodies and serum inflammatory markers (complement C3 and C4) revealed
that C4 correlated with miR-16-5p and inversely with miR125a-5p, miR155-5p correlated with
anti-SSA and anti-Sm, whilst miR16-5p inversely correlated with anti-Sm antibody. Despite
differences in the expression of 5 miRNAs being observed between SLE patients and HC, there
were no observed correlation with anti-dsDNA, anti-SSB/Ro, and anti-RNP. In addition, Overall,
we found a differential expression pattern of miRNAs in a large Hispanic cohort that has not been
studied before.
The varied nature of SLE has been attributed partly to the genetics involved, with different
ethnicities portraying different forms of the disease. Disease progression and organ involvement
have been reported to be different, with black and Hispanic populations having a higher incidence
rate and more severe lupus nephritis compared with Caucasians (2, 20). Array studies on human T
cells have shown changes in gene expression in different ethnicities that relate to disease activity
and clinical presentation (21). Therefore, population specific studies are an important approach to
characterize SLE in different cohorts because of the heterogeneous nature of SLE.
The Type I IFN pathway is a major contributing pathway implicated in the persistent
inflammation that occurs in SLE. It has been shown that miR-146a negatively regulates the Type
1 IFN pathway by direct interference with two IFN-related transcription factors, IRF5 and STAT1
(9 ).Therefore, reduced expression of miR-146a has been implicated in SLE pathogenesis, and mice
deficient in miR-146a show severe autoimmune phenotypes (22 ).We found the levels of miR-

20
146a-5p to be higher in SLE patients than HC in this study, and this was consistent with results
from a study in Danish and Swedish cohorts (23). Studies by Tang et al (9 ) and Wang et al (22)
in Chinese cohorts reported decreased levels of miR-146a l in peripheral blood morphonuclear cells
(PBMCs) as well as serum. Dai et al also reported decreased levels in splenic T cells and
splenocytes in three murine lupus models (24). These overall divergent results point to the
possibility of variations in the expression of miRNAs in SLE in different ethnicities. Of note is that
these studies were done on different tissue types and this could explain in part the contrasting results
from different studies as it has been shown that miRNA levels vary in different cell compartments,
subtypes, and tissue types.
Some miRNAs have multiple effects on the type 1 IFN pathway and Toll-Like Receptor
signaling, resulting in defective B and T cell interaction. These are central pathways in the
pathogenesis of SLE (25). It has been reported that miR-155 promotes inflammation and type1 IFN
signaling, as well as negatively regulates the expression of CD1d, a class-1 like MHC molecule,
on the B cells of SLE patients (25, 26). CD1d deficiency was reported to aggravate disease
symptoms and further impair the antigen presenting ability of B cells. Our study revealed reduced
expression of miR-155 in the SLE group, and this corroborates results from Wang et al (22) and
is in keeping with the proposed reduced serum expression of miR-155 in SLE.
The production of inflammatory cytokines and chemokines is central in SLE and miR-125a has
been implicated in the activity of RANTES, an inflammatory chemokine. A study by Zhao et al
reported that miR-125a negatively regulates RANTES; therefore, reduced expression of miR-125a
contributes to the elevated expression of RANTES in SLE (13). Our study revealed decreased
expression of miR-125a, consistent with these findings. In contrast, a study on a Caucasian cohort
reported elevated levels of miR-125a (23) and could be due to differential miRNA expression
patterns in different races or ethnic cohorts.
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Although miR-16 and miR-451a have been implicated in the pathogenesis of SLE, the exact
mechanisms have not been well studied. In addition, little data exist on the expression patterns in
SLE, as well as their correlation to disease activity. A recent study by Cheng et al reported that the
over expression of miR-451a was associated with increased levels of CD4+CD69+, CD4+/CD8+
T cells, and the levels of the serum cytokines IL-17a and IL-4

(27). Both promoted the

inflammatory process in SLE. The inflammatory regulatory factor 8 (IRF8) was identified as a
possible target of miR-451a. Our study results showed the over expression of miR-451a and miR16 in the SLE group. This sets an important platform to further study their role in immune cell
activity in SLE.
Measures of complement activation are part of the standard laboratory tests done on most SLE
patients on a regular basis. These include complement C3 and C4, which may serve as an indication
of active disease because they are acute phase proteins (28). The deficiency of early complement
proteins, mainly C1 and C4, is strongly associated with development of SLE (29). We observed a
correlation between miR16-5p, miR125a-3p and complement C4. There was no observed
correlation between the differentially expressed miRNAs and complement C3.
A central characteristic of SLE is the production of autoantibodies and several are implicated
in the diagnosis of disease. We observed an inverse correlation between miR16-5p, miR155-5p and
anti-Sm antibody; miR-155-5p and anti-SSA antibody. Of interest is that anti-Sm antibody has been
linked with lupus nephritis (30 ) and anti-SSA antibody has been characterized in a group of patients
that present with cutaneous SLE and photosensitivity (31 ). Our population cohort displayed renal
and cutaneous disease as the highest prevalence. This suggests a role of miR16-5p and miR155-5p
in the production of these autoantibodies and their possible contribution to these clinical
manifestations in SLE. Further characterization in these clinical phenotypes would provide better
insight.
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There were no observed correlations between anti-dsDNA, anti-SSB, and anti-RNP with the
differentially expressed miRNAs. While autoantibodies serve as important diagnostic criteria for
SLE and other autoimmune diseases, the presence of autoantibodies alone is not a distinct indicator
of disease activity, and multiple factors should be considered.
Whilst B and T cells are the key players in autoimmunity and autoantibody production in SLE,
tissue damage occurs due to chronic inflammation after immune complex deposition in end organs
such as kidneys, lungs, or vasculature. Abnormalities in neutrophils (increased activation and
apoptosis) (5, 32, 33 ) and the identification of an abnormal subset of low density granulocytes
provides support that these cells are central in driving inflammation and resulting in tissue damage
in SLE (34, 35 ). Using neutrophil-like NB4 cells, we have shown that immune complex-induced
activation of neutrophils (oxidative burst) are enhanced by overexpression of SLE-upregulated
miR451a or inhibition of SLE-downregulated miR125a. Our results support the hypothesis that
dysregulated miRNAs in SLE may play a role in SLE pathogenesis and tissue damage.
There were a few limitations in this study. By design, the current study was restricted to 10
miRNAs chosen for analysis. Whilst a global profiling tool such as microarrays offers a more
comprehensive initial screening method for miRNA expression patterns, use of this technology in
our analysis was prohibitively expensive. Therefore, we selected the miRNAs of interest from
literature and from previous studies that have been done to identify SLE- related miRNAs.
Whilst most studies have focused on PBMCs in their miRNA profiling analysis, this present
study examined cell-free circulating miRNAs in serum. Although serum and plasma naturally have
lower levels of miRNAs compared to PBMCs, they offer an easier tool for analysis and cast a
broader net on the levels of miRNAs that are not limited to specific cell types.
Our study reports novel data in a large Hispanic cohort showing that serum miR-16-5p,
miR126-5p, miR-451a and miR-146a-3p are over expressed in SLE patients, with reduced

23
expression of miR-155-5p and miR-125a-3p. In addition, there is an inverse correlation between
miR16-5p and anti-Sm antibody, miR-146a-5p and anti-SSA antibody. Collectively, these
differential expression patterns could contribute to the pathogenesis of SLE seen in this cohort and
offers an important platform for future studies on the exact mechanisms of these miRNAs in SLE.
We also show increased oxidative response in neutrophil-like NB4 cells stably transfected with
miR125a and miR451a, pointing to the potential role of these miRNAs in neutrophil-mediated
inflammation in SLE.
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